title: Mechanisms of human motor cortex facilitation induced by subthreshold 5-Hz repetitive transcranial magnetic stimulation.
abstract: Our knowledge about the mechanisms of human motor cortex facilitation induced by repetitive transcranial magnetic stimulation (rTMS) is still incomplete. Here we used pharmacological conditioning with carbamazepine, dextrometorphan, lorazepam, and placebo to elucidate the type of plasticity underlying this facilitation, and to probe if mechanisms reminiscent of long-term potentiation are involved. Over the primary motor cortex of 10 healthy subjects, we applied biphasic rTMS pulses of effective posterior current direction in the brain. We used six blocks of 200 pulses at 5-Hz frequency and 90% active motor threshold intensity and controlled for corticospinal excitability changes using motor-evoked potential (MEP) amplitudes and latencies elicited by suprathreshold pulses before, in between, and after rTMS. Target muscle was the dominant abductor digiti minimi muscle; we coregistered the dominant extensor carpi radialis muscle. We found a lasting facilitation induced by this type of rTMS. The GABAergic medication lorazepam and to a lesser extent the ion channel blocker carbamazepine reduced the MEP facilitation after biphasic effective posteriorly oriented rTMS, whereas the N-methyl-d-aspartate receptor-antagonist dextrometorphan had no effect. Our main conclusion is that the mechanism of the facilitation induced by biphasic effective posterior rTMS is more likely posttetanic potentiation than long-term potentiation. Additional findings were prolonged MEP latency under carbamazepine, consistent with sodium channel blockade, and larger MEP amplitudes from extensor carpi radialis under lorazepam, suggesting GABAergic involvement in the center-surround balance of excitability.
authors.affiliation: Dept. of Clinical Neurophysiology, Univ. of Goettingen, Goettingen, Germany. msommer@gwdg.de
authors.forename: Martin
authors.initials: M
authors.lastname: Sommer
authors.forename: Milena
authors.initials: M
authors.lastname: Rummel
authors.forename: Christoph
authors.initials: C
authors.lastname: Norden
authors.forename: Holger
authors.initials: H
authors.lastname: Rothkegel
authors.forename: Nicolas
authors.initials: N
authors.lastname: Lang
authors.forename: Walter
authors.initials: W
authors.lastname: Paulus
mesh_terms: D000328:Adult; D002220:Carbamazepine / Q000494:pharmacology; D019054:Evoked Potentials, Motor; D005260:Female; D018757:GABA Modulators / Q000494:pharmacology; D006801:Humans; D017774:Long-Term Potentiation; D008140:Lorazepam / Q000494:pharmacology; D008297:Male; D009044:Motor Cortex / Q000187:drug effects / Q000502:physiology*; D018482:Muscle, Skeletal / Q000294:innervation / Q000502:physiology; D010890:Pirenzepine / Q000031:analogs & derivatives / Q000494:pharmacology; D011930:Reaction Time; D016194:Receptors, N-Methyl-D-Aspartate / Q000037:antagonists & inhibitors; D012684:Sensory Thresholds; D026941:Sodium Channel Blockers / Q000494:pharmacology; D050781:Transcranial Magnetic Stimulation
chemical_list: C470406:4'-N-demethylolanzapine; D018757:GABA Modulators; D016194:Receptors, N-Methyl-D-Aspartate; D026941:Sodium Channel Blockers; D002220:Carbamazepine; D010890:Pirenzepine; D008140:Lorazepam
keywords: carbamazepine; dextrometorphan; lorazepam; plasticity; transcranial magnetic stimulation